Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Diamedica Therapeutics ( (DMAC) ) just unveiled an announcement.
On August 12, 2025, DiaMedica Therapeutics Inc. entered into a Sales Agreement with TD Securities (USA) LLC, allowing the company to offer and sell its common shares through TD Cowen, with a potential aggregate offering amount of up to $100 million. This agreement, which involves an ‘at the market offering’, outlines that TD Cowen will act as the sales agent, earning up to 3% of the gross proceeds from the sales. The proceeds from these sales will depend on the number of shares sold and their offering price, with the company agreeing to cover certain costs and liabilities for TD Cowen. The sales will be conducted under a shelf registration statement filed with the SEC, which has not yet been declared effective.
The most recent analyst rating on (DMAC) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Diamedica Therapeutics stock, see the DMAC Stock Forecast page.
Spark’s Take on DMAC Stock
According to Spark, TipRanks’ AI Analyst, DMAC is a Neutral.
Diamedica Therapeutics faces significant financial hurdles with no revenue and rising net losses, leading to a low financial performance score. Technical analysis presents mixed signals, adding uncertainty. Despite this, the company’s optimistic guidance and significant progress in clinical trials offer some potential, reflected in a moderate earnings call score. However, the speculative nature of its valuation due to the absence of earnings and dividends remains a key risk.
To see Spark’s full report on DMAC stock, click here.
More about Diamedica Therapeutics
Average Trading Volume: 292,116
Technical Sentiment Signal: Buy
Current Market Cap: $236.7M
For an in-depth examination of DMAC stock, go to TipRanks’ Overview page.